iRhythm Holdings Appoints Jason Patten to Board of Directors
iRhythm Holdings Announces Appointment of Jason Patten to Board of Directors
Key Highlights from the SEC Filing
- Appointment of Jason Patten: Effective March 12, 2026, Jason Patten has been appointed as a director of the Board of iRhythm Holdings, Inc., and as a member of the Audit Committee.
- Term and Independence: Mr. Patten will serve until the 2026 Annual Meeting of stockholders and is considered an independent director under both SEC and Nasdaq rules, including SEC Rule 10A-3 for audit committee members.
- Compensation Package:
- Initial retainer grant of restricted stock units valued at \$300,000, vesting annually over three years following March 12, 2026.
- Annual cash retainer of \$55,000 for Board service.
- Additional \$10,000 per year for Audit Committee service.
- The restricted stock units will accelerate and vest fully upon a change of control, as long as Mr. Patten is in service at that time.
- Indemnification: Mr. Patten will enter into the company’s standard form of indemnification agreement for directors and executive officers.
- Prior Relationship: Before joining the Board, Mr. Patten served as an advisor to the President and CEO, receiving a one-time payment of \$86,771 for services rendered.
- Disclosure: There are no arrangements or relationships that would require disclosure under Item 404(a) of Regulation S-K, and Mr. Patten was not selected as a director via any arrangements or understandings with other persons.
Potential Price-Sensitive Information for Shareholders
- Board Strengthening: The appointment of Mr. Patten, with extensive experience in healthcare and financial services (including senior roles at UnitedHealth Group and MoneyGram International), is expected to enhance the Board’s oversight, especially in financial and audit matters.
- Equity Awards: The \$300,000 restricted stock unit grant, which vests over three years and accelerates upon a change of control, may signal potential Board confidence in the company’s future or upcoming strategic changes (such as M&A activity).
- Audit Committee Expertise: Mr. Patten’s role in the Audit Committee strengthens compliance and governance, which is critical for investor confidence, especially as iRhythm is traded on the NASDAQ Global Select Market under the symbol “IRTC”.
- No Related Party Transactions: The filing confirms there are no material related party transactions or conflicts, supporting transparency and good governance.
Additional Details
- Company Overview: iRhythm Holdings is a leading digital healthcare company focused on cardiac monitoring, combining wearable biosensors, cloud analytics, and proprietary algorithms to provide actionable clinical data.
- Corporate Information:
- Incorporated in Delaware.
- Principal executive offices at 699 8th Street, Suite 600, San Francisco, CA 94103.
- Chief Financial Officer: Daniel Wilson (signed the report).
- Securities Information:
- The company’s common stock trades under “IRTC” on the NASDAQ Global Select Market.
- Emerging Growth Company status: The company is not an emerging growth company as defined by SEC rules.
- Regulation FD Disclosure: The company announced Mr. Patten’s appointment via a press release furnished as Exhibit 99.1, but noted that this information is not deemed “filed” for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless specifically stated.
Implications for Shareholders and Investors
The appointment of Jason Patten is a significant event for iRhythm Holdings, as it brings fresh expertise to the Board and Audit Committee. His compensation structure, especially the accelerated vesting upon a change of control, could indicate potential strategic changes or confidence in the company’s long-term outlook. Investors should monitor for any further Board or executive changes, potential M&A activity, or shifts in governance that could affect the share price. The company’s commitment to strong governance and transparency is reinforced by the absence of related party transactions and the adherence to SEC and Nasdaq standards.
Press Release Summary
The official press release highlights Mr. Patten’s broad experience in healthcare, financial services, global product development, and strategic marketing. He holds an MBA from the University of St. Thomas and a BS in Marketing from Minnesota State University, Mankato. The release reiterates iRhythm’s vision to deliver better data, insights, and health outcomes through digital technology.
Investor Contacts
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult with professional advisors before making investment decisions. Information presented is based on SEC filings and company press releases as of March 12, 2026, and may be subject to change without notice.
View iRhythm Holdings, Inc. Historical chart here
